Psychopharmacology

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

An expert shares 7 principles for clinicians to consider when prescribing multiple medications for a patient.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Clinicians should carefully weigh the risks and benefits of each prescribed medication for an older adult with neuropsychiatric diseases and periodically review all prescribed medications. Learn more here.

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.

What are the risks and benefits of antipsychotic polypharmacy for the treatment of schizophrenia?

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Here are highlights from the week in Psychiatric Times.

Polypharmacy is often overlooked in patients with significant traumatic brain injury. How can you best manage medication in these patients?

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The company has announced plans to submit the NDA in the first half of 2025.

“The findings emphasize the importance of monitoring the use of psychotropic combinations, particularly among vulnerable populations.”

Here are highlights from the week in Psychiatric Times.

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.

Here’s how an integrated psychosocial and pharmacologic approach can enhance SUD treatment.

Here are highlights from the last day of this year’s APA Annual Meeting.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.